Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
117 hedge funds and large institutions have $999M invested in Crinetics Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 39 reducing their positions, and 16 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 39
2.68% more ownership
Funds ownership: 93.21% → 95.89% (+2.7%)
1% less funds holding
Funds holding: 118 → 117 (-1)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
21% less capital invested
Capital invested by funds: $1.26B → $999M (-$258M)
44% less funds holding in top 10
Funds holding in top 10: 9 → 5 (-4)
67% less call options, than puts
Call options by funds: $2K | Put options by funds: $6K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$8.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$8.1M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.27M |
| 4 |
Millennium Management
New York
|
+$4.11M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$39.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.79M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.25M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$3.46M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$2.76M |
CRNX Hedge Fund Activity: Q1 2022 in Review
117 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2022, worth a combined $999M — down 21% from $1.26B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of CRNX and 15 opened new positions — a net loss of 1 holder — while 39 trimmed existing stakes and 43 added.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $8.6M. The largest seller was Frazier Management, exiting entirely with an estimated $39.3M sold.
- 117 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2022, down from 118 in Q4 2021.
- Funds reported $999M of Crinetics Pharmaceuticals stock for Q1 2022, down 21% quarter-over-quarter.
- 15 funds opened new Crinetics Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of -1 holder.
- The largest Crinetics Pharmaceuticals buyer in Q1 2022 was Novo Holdings A/S, an estimated $8.6M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $39.3M sold.
Based on aggregated 13F filings for Q1 2022.